KR101936968B1 - 주사용 서방형 제제 - Google Patents

주사용 서방형 제제 Download PDF

Info

Publication number
KR101936968B1
KR101936968B1 KR1020137011618A KR20137011618A KR101936968B1 KR 101936968 B1 KR101936968 B1 KR 101936968B1 KR 1020137011618 A KR1020137011618 A KR 1020137011618A KR 20137011618 A KR20137011618 A KR 20137011618A KR 101936968 B1 KR101936968 B1 KR 101936968B1
Authority
KR
South Korea
Prior art keywords
solution
active ingredient
preparation
castor oil
crystals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137011618A
Other languages
English (en)
Korean (ko)
Other versions
KR20130139978A (ko
Inventor
다까시 나까가와
노리마사 고세키
Original Assignee
다이닛본 스미토모 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이닛본 스미토모 세이야꾸 가부시끼가이샤 filed Critical 다이닛본 스미토모 세이야꾸 가부시끼가이샤
Publication of KR20130139978A publication Critical patent/KR20130139978A/ko
Application granted granted Critical
Publication of KR101936968B1 publication Critical patent/KR101936968B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020137011618A 2010-10-18 2011-10-18 주사용 서방형 제제 Expired - Fee Related KR101936968B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39406910P 2010-10-18 2010-10-18
US61/394,069 2010-10-18
PCT/JP2011/074375 WO2012053654A1 (en) 2010-10-18 2011-10-18 Sustained-release formulation for injection

Publications (2)

Publication Number Publication Date
KR20130139978A KR20130139978A (ko) 2013-12-23
KR101936968B1 true KR101936968B1 (ko) 2019-01-09

Family

ID=45933169

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137011618A Expired - Fee Related KR101936968B1 (ko) 2010-10-18 2011-10-18 주사용 서방형 제제

Country Status (7)

Country Link
US (3) US9469630B2 (https=)
EP (1) EP2629775A4 (https=)
JP (4) JP5893616B2 (https=)
KR (1) KR101936968B1 (https=)
CN (3) CN107625728A (https=)
CA (1) CA2814840C (https=)
WO (1) WO2012053654A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
WO2014084921A1 (en) * 2012-11-27 2014-06-05 Rose Stuart Pharmaceutical manufacturing method and compositions
WO2014152562A1 (en) * 2013-03-15 2014-09-25 Epizyme, Inc. Injectable formulations for treating cancer
TW201609145A (zh) * 2013-12-25 2016-03-16 參天製藥股份有限公司 注射劑及形成緩釋（ｄｅｐｏｔ）之方法
WO2016044649A1 (en) * 2014-09-17 2016-03-24 Epizyme, Inc. Injectable formulations for treating cancer
KR101792414B1 (ko) * 2016-05-19 2017-11-01 삼성전기주식회사 박막 커패시터 및 그 제조방법
CN105963253A (zh) * 2016-06-19 2016-09-28 朱武欣 一种罗替戈汀长效水性混悬型注射剂
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent
JPWO2018043613A1 (ja) * 2016-08-31 2019-06-24 大日本住友製薬株式会社 水性懸濁型製剤
US10252229B2 (en) * 2017-06-30 2019-04-09 Snowie LLC System comprising a pump attached to a tank casing for mixing a fluid
JPWO2019167978A1 (ja) 2018-02-28 2021-02-04 大日本住友製薬株式会社 溶出が制御された水性懸濁型医薬製剤
CN111989102A (zh) * 2018-02-28 2020-11-24 大日本住友制药株式会社 水性混悬液型药物制剂
JP7214103B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214100B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JP7214102B2 (ja) * 2019-01-18 2023-01-30 株式会社大一商会 遊技機
JPWO2020179925A1 (https=) * 2019-03-07 2020-09-10
CN110478131B (zh) * 2019-08-05 2022-01-11 思必康（厦门）新材料有限公司 一种pH响应变色的纱布及其制备方法和该纱布的应用
US11041740B1 (en) 2019-12-20 2021-06-22 EmpNia Inc. Method and apparatus for real time respiratory gating signal generation and detection of body deformation using embedded fiber Bragg gratings
EP4126882A1 (en) * 2020-03-27 2023-02-08 Boston Scientific Scimed Inc. Methods for crystallization of drugs
WO2022034489A1 (en) * 2020-08-11 2022-02-17 Auxilla Pharmaceuticals And Research Llp A non-aqueous suspension of anticancer agent
CA3210098A1 (en) 2021-02-24 2022-09-01 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
CN116848108A (zh) 2021-03-31 2023-10-03 四川科伦药物研究院有限公司 一种鲁拉西酮可注射混悬液及其制备方法
CN120078778A (zh) * 2024-09-25 2025-06-03 山东百诺医药股份有限公司 一种伏硫西汀酯药物组合物及其制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6169084B1 (en) 1997-09-30 2001-01-02 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
FI105074B (fi) 1997-12-31 2000-06-15 Leiras Oy Farmaseuttisen formulaation valmistusmenetelmä
HK1041199B (en) 1998-09-30 2005-03-18 Eli Lilly & Company 2-Methyl-thiophenone-benzodiazine formula
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US20040022862A1 (en) 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
WO2002078673A1 (fr) 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Procede de production d'un medicament sous forme de granules fins
JP4175800B2 (ja) 2001-11-27 2008-11-05 住友化学株式会社 イミド誘導体の製造方法
DE10218110A1 (de) 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Arzneimittelhilfsstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
KR101085806B1 (ko) 2003-07-29 2011-11-22 다이닛본 스미토모 세이야꾸 가부시끼가이샤 이미드 화합물의 제조 방법
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
UA82561C2 (uk) 2003-10-23 2008-04-25 Оцука Фармасьютикалз Ко., Лтд. Стерильна ін'єкційна композиція арипіпразолу з контрольованим вивільненням, спосіб її виготовлення та спосіб лікування шизофренії
CN101106972A (zh) 2004-11-16 2008-01-16 伊兰制药国际有限公司 注射用纳米微粒奥氮平制剂
SI1838716T1 (sl) 2005-01-05 2011-10-28 Lilly Co Eli Olanzapin pamoat dihidrat
RU2407529C2 (ru) 2005-04-13 2010-12-27 Пфайзер Продактс Инк. Инъецируемые препаративные формы депо и способы обеспечения замедленного высвобождения композиций, состоящих из наночастиц
DK1884242T3 (da) * 2005-05-26 2013-05-06 Dainippon Sumitomo Pharma Co Farmaceutisk sammensætning omfattende lurasidon
US8283352B2 (en) * 2005-06-13 2012-10-09 Dainippon Sumitomo Pharma Co., Ltd. Solubilization preparation
CA2622758A1 (en) 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
WO2007106768A2 (en) 2006-03-14 2007-09-20 Merck & Co., Inc. Processes and apparatuses for the production of crystalline organic microparticle compositions by micro-milling and crystallization on micro-seed and their use
BRPI0820745A2 (pt) 2007-12-13 2015-06-16 Novartis Ag Compostos orgânicos

Also Published As

Publication number Publication date
US20190010149A1 (en) 2019-01-10
JP6173502B2 (ja) 2017-08-02
CN103249416B (zh) 2019-06-04
JP5893616B2 (ja) 2016-03-23
EP2629775A1 (en) 2013-08-28
JP6410889B2 (ja) 2018-10-24
WO2012053654A1 (en) 2012-04-26
JP2017206543A (ja) 2017-11-24
JP2013543481A (ja) 2013-12-05
JP2016128503A (ja) 2016-07-14
CN103249416A (zh) 2013-08-14
CN107595771A (zh) 2018-01-19
EP2629775A4 (en) 2014-06-11
US20120091022A1 (en) 2012-04-19
CA2814840A1 (en) 2012-04-26
JP2019006822A (ja) 2019-01-17
US9469630B2 (en) 2016-10-18
CN107625728A (zh) 2018-01-26
US20160158228A1 (en) 2016-06-09
CA2814840C (en) 2018-08-28
KR20130139978A (ko) 2013-12-23

Similar Documents

Publication Publication Date Title
KR101936968B1 (ko) 주사용 서방형 제제
TWI405590B (zh) 微粉碎化有機化合物粒子之製法
JP2007532619A (ja) 懸濁したガラス粒子を含有する液体
CN114748428A (zh) 一种高载药量的盐酸卡利拉嗪长效缓释微球及其制备方法
AU2016349169A1 (en) Physically and chemically stable oral suspensions of Givinostat
CN103263385B (zh) 一种塞来昔布长效纳米注射剂及其制备方法
EP3058958A1 (en) Anidulafungin composition
WO2022151994A1 (zh) 一种氨氯地平干混悬剂及其制备方法
CN110167532B (zh) 可注射的悬浮液
MD3769753T2 (ro) Procedeu de preparare a suspensiilor de nanocristale de propionat de fluticazonă Forma A apoase oftalmice sterile
CN107349181A (zh) 含有瑞巴派特和聚维酮的眼科水悬浮液及其制备方法
CN102481287A (zh) 含维生素c或其衍生物的替莫唑胺药物组合物及其制备方法
JP7589393B2 (ja) 滅菌処理したヘテロシクリデンアセトアミド誘導体含有懸濁液
CN111148513B (zh) 一种包含地佐辛类似物酯的缓释混悬液及其制备方法
CN102048702A (zh) 一种联苯双酯纳米结晶制剂及其制备方法
JP7776905B2 (ja) プロゲリニンを含むナノ懸濁液及びその製造方法
EP4382096A1 (en) Lyophilized vortioxetine pamoate powder for injection and preparation method therefor
RU2837640C2 (ru) Лиофилизированный порошок памоата вортиоксетина для инъекций и способ его получения
WO2019213286A1 (en) Extended release suspension formulation of lurasidone
AU2017303975A1 (en) Process for preparing sterile aripiprazole formulation
CN116262100A (zh) 一种氟维司群凝胶组合物及其制备方法和应用

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220104

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220104